A phase I/II trial to combine Abexinostat with Ibrutinib against Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)

Trial Profile

A phase I/II trial to combine Abexinostat with Ibrutinib against Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Abexinostat (Primary) ; Ibrutinib (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2017 New trial record
    • 01 Dec 2017 According to a Xynomic Pharma media release, this trial is to be led by Memorial Sloan Kettering Cancer Center's (MSK's) Drs. Anita Kumar and Anas Younes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top